Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 4
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06905522Phase 3Recruiting

A PAN-USR TB Multi-Center Trial

Role: collaborator

NCT06403943Phase 4Recruiting

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

Role: collaborator

NCT05831969Phase 2Unknown

Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

Role: lead

All 3 trials loaded